Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive, multi-drug resistant cells through its action on the p-glycoprotein pump
- 31 December 2006
- journal article
- Published by Elsevier in Medical Hypotheses
- Vol. 66 (4) , 715-731
- https://doi.org/10.1016/j.mehy.2005.11.005
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005
- Differential sensitivities of trastuzumab (Herceptin®)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitorsBreast Cancer Research and Treatment, 2005
- Activation of theMDR1Upstream Promoter in Breast Carcinoma as a Surrogate for Metastatic InvasionClinical Cancer Research, 2004
- ROS stress in cancer cells and therapeutic implicationsDrug Resistance Updates, 2004
- Enhancement of antitumour activity of cisplatin by N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine· HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatinEuropean Journal Of Cancer, 1997
- Functional Reconstitution of P-glycoprotein Reveals an Apparent Near Stoichiometric Drug Transport to ATP HydrolysisJournal of Biological Chemistry, 1996
- Evidence that tamoxifen is a histamine antagonistBiochemical and Biophysical Research Communications, 1985
- A diphenylmethane derivative selective for the anti-estrogen binding site may help define its biological roleBiochemical and Biophysical Research Communications, 1984
- A diphenylmethane derivative specific for the antiestrogen binding site found in rat liver microsomesBiochemical and Biophysical Research Communications, 1984
- On the Origin of Cancer CellsScience, 1956